Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been given a $90.00 price target by research analysts at Ladenburg Thalmann Financial Services in a research note issued to investors on Monday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Ladenburg Thalmann Financial Services’ target price would indicate a potential upside of 15.76% from the company’s previous close.

Other research analysts have also issued reports about the stock. UBS AG began coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 29th. They set a “neutral” rating and a $55.00 target price on the stock. Morgan Stanley restated an “equal weight” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, July 10th. Chardan Capital set a $95.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, May 5th. BMO Capital Markets started coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, April 17th. They issued an “outperform” rating and a $73.00 price target on the stock. Finally, Vetr lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 price target on the stock. in a research report on Monday, May 15th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $78.83.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 1.26% during midday trading on Monday, reaching $77.75. The company’s stock had a trading volume of 728,324 shares. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $86.92. The company has a 50 day moving average of $73.05 and a 200-day moving average of $53.57. The stock’s market capitalization is $6.70 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by $0.03. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The firm had revenue of $19 million for the quarter, compared to analyst estimates of $22.91 million. During the same quarter last year, the firm earned ($1.21) earnings per share. The company’s revenue was up 160.3% compared to the same quarter last year. Equities research analysts predict that Alnylam Pharmaceuticals will post ($5.24) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) Given a $90.00 Price Target at Ladenburg Thalmann Financial Services” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/ladenburg-thalmann-financial-services-increases-alnylam-pharmaceuticals-inc-alny-price-target-to-90-00/1444359.html.

In other Alnylam Pharmaceuticals news, major shareholder Sanofi acquired 297,501 shares of the company’s stock in a transaction dated Wednesday, May 31st. The stock was bought at an average price of $71.87 per share, with a total value of $21,381,396.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Michael Mason sold 9,375 shares of the stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $70.00, for a total transaction of $656,250.00. Following the completion of the sale, the vice president now directly owns 5,625 shares of the company’s stock, valued at approximately $393,750. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 64,125 shares of company stock worth $4,325,000. 4.30% of the stock is currently owned by insiders.

Several large investors have recently added to or reduced their stakes in ALNY. Dodge & Cox acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at about $344,633,000. BlackRock Inc. raised its stake in Alnylam Pharmaceuticals by 34,755.2% in the first quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after buying an additional 4,732,617 shares during the last quarter. Perceptive Advisors LLC raised its stake in Alnylam Pharmaceuticals by 831.4% in the first quarter. Perceptive Advisors LLC now owns 1,103,475 shares of the biopharmaceutical company’s stock valued at $56,553,000 after buying an additional 985,000 shares during the last quarter. Norges Bank acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at about $24,885,000. Finally, Rockefeller Financial Services Inc. raised its stake in Alnylam Pharmaceuticals by 4,724.4% in the first quarter. Rockefeller Financial Services Inc. now owns 506,223 shares of the biopharmaceutical company’s stock valued at $25,944,000 after buying an additional 495,730 shares during the last quarter. 89.22% of the stock is owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.